

Substitute for Form PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER 034100-003 U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/500,841
INTERNATIONAL APPLICATION NO. PCT/JP2002/013879	INTERNATIONAL FILING DATE 27 December 2002 (27.12.2002)	PRIORITY DATE CLAIMED 09 January 2002 (09.01.2002)
TITLE OF INVENTION GLYCOSYLTRANSFERASE GNT-V HAVING NEOVASCULARIZATION ACTION (AS AMENDED)		
APPLICANT(S) FOR DO/EO/US Naoyuki TANIGUCHI et al.		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: <ol style="list-style-type: none"> <input type="checkbox"/> This is a FIRST submission to items concerning a filing under 35 U.S.C. 371. <input checked="" type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (22) indicated below. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31). <input type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). <input type="checkbox"/> has been communicated by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> <input type="checkbox"/> is attached hereto. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). <input type="checkbox"/> have been communicated by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input type="checkbox"/> have not been made and will not be made. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). <input checked="" type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). <p>Items 11 to 21 below concern document(s) or information included:</p> <ol style="list-style-type: none"> <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. <input type="checkbox"/> A FIRST preliminary amendment. <input checked="" type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. <input type="checkbox"/> A substitute specification. <input type="checkbox"/> A change of power of attorney and/or address letter. <input checked="" type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 C.F.R. 1.821 - 1.825. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). <input checked="" type="checkbox"/> Other items or information: <u>1) Form PCT/IB/338; 2) Paper copy of Sequence Listing (included with the Preliminary Amendment), 3) Declaration Pursuant to 37 C.F.R. Sections 1.821-1.825, and 4) Copy of Notice mailed on December 15, 2004.</u> 		

U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/500,841		INTERNATIONAL APPLICATION NO. PCT/JP2002/013879		ATTORNEY'S DOCKET NUMBER 034100-003	
--	--	---	--	---	--

21. ☒ Applicant(s) requests that the published application include the following assignment information: Suntory Limited, Osaka, Japan.

22. ☒ The following fees are submitted:

Basic Filing Fee (1631)				\$ 0.00
Surcharge of \$130.00 (1617) for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)). <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30				\$ 130.00
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$
Total Claims	-20 =	0	X \$50.00 (1615)	\$ 0.00
Independent Claims	- 3 =	0	X \$200.00 (1614)	\$ 0.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$360.00 (1616)
Examination Fee				+ \$200.00 (1633)
Search Fee				+ \$500.00 (1632)
App. Size Fee (add \$250.00 for each add'l 50 sheets exceeding 100 sheets)				
TOTAL OF ABOVE CALCULATIONS =				\$ 130.00
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				+ \$ 0.00
SUBTOTAL =				\$ 130.00
Processing fee of \$130.00 (1618) for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492(f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30				\$ 0.00
TOTAL NATIONAL FEE =				\$ 130.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 (8021) per property +				
TOTAL FEES ENCLOSED =				\$ 130.00
				Amount to be refunded :
				charged :

a. ☐ A check in the amount of _____ to cover the above fees is enclosed.

b. ☒ Please charge my Deposit Account No. 02-4800 in the amount of \$ 130.00 to cover the above fees. A duplicate copy of this sheet is enclosed.


c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-4800. A duplicate copy of this sheet is enclosed.

d. ☐ Charge _____ to credit card. Form PTO-2038 is attached.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Burns, Doane, Swecker & Mathis, L.L.P.
P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620


 SIGNATURE
 Susan M. Dadio
 NAME
 40,373 February 15, 2005
 REGISTRATION NO. DATE

02/18/2005 GFREY1 00000087 024800 10500841

01 FEB 1617 130.00 DA



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/500,841	FIRST NAMED APPLICANT Naoyuki Taniguchi	ATTY. DOCKET NO. 034100-003
---	--	--------------------------------

INTERNATIONAL APPLICATION NO. PCT/JP02/13879

LA. FILING DATE 12/27/2002	PRIORITY DATE 01/09/2002
-------------------------------	-----------------------------

21839
BURNS DOANE SWECKER & MATHIS L L P
POST OFFICE BOX 1404
ALEXANDRIA, VA 22313-1404

CONFIRMATION NO. 7031
371 FORMALITIES LETTER



OC000000014760202

Date Mailed: 12/15/2004

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Copy of the International Application filed on 07/07/2004
- English Translation of the IA filed on 07/07/2004
- Copy of the International Search Report filed on 07/07/2004
- Copy of IPE Report filed on 07/07/2004
- Preliminary Amendments filed on 07/07/2004
- Information Disclosure Statements filed on 07/07/2004
- Biochemical Sequence Diskette filed on 07/07/2004
- Biochemical Sequence Listing filed on 07/07/2004
- U.S. Basic National Fees filed on 07/07/2004
- Priority Documents filed on 07/07/2004

Handwritten: RG/smd
DEC 17 2004
1220-04
DEC 22 2004
Handwritten: 12/30
Handwritten: CR

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- \$130 Surcharge for providing the oath or declaration later than 30 months from the priority date (37 CFR 1.492(e)) is required.

SUMMARY OF FEES DUE:

Total additional fees required for this application is \$130 for a Large Entity:

- \$130 Late oath or declaration Surcharge.

Handwritten: M. D. T.

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of Annex C of the Administrative Instructions and 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
 - APPLICANT MUST PROVIDE:
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase PatentIn Software, call (703) 306-2600
 - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*


VONDA M WALLACE

Telephone: (703) 305-3736

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/500,841	PCT/JP02/13879	034100-003

BIOTECHNOLOGY
SYSTEMS
BRANCH



RAW SEQUENCE LISTING
ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number:

10/500,841

Source:

PCT

Date Processed by STIC:

7/15/04

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER
VERSION 4.2 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND
TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm>) , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 06/05/04):
U.S. Patent and Trademark Office, 220 20th Street S., Customer Window, Mail Stop Sequence, Crystal Plaza Two, Lobby, Room 1B03, Arlington, VA 22202

Revised 05/17/04

MAIL THIS COPY WITH 905



PCT

RAW SEQUENCE LISTING
PATENT APPLICATION: US/10/500,841

DATE: 07/15/2004
TIME: 10:17:00

Input Set : A:\PTO.FG.txt
Output Set: N:\CRF4\07152004\J500841.raw

3 <110> APPLICANT: SUNTORY LIMITED
5 <120> TITLE OF INVENTION: Glycosyltransferase GnT-V having neovascularization action
7 <130> FILE REFERENCE: DS07F927
!--> 9 <140> CURRENT APPLICATION NUMBER: US/10/500,841
!--> 9 <141> CURRENT FILING DATE: 2004-07-07
9 <150> PRIOR APPLICATION NUMBER: PCT/JP02/13879
10 <151> PRIOR FILING DATE: 2002-12-27
12 <160> NUMBER OF SEQ ID NOS: 13

ERRORED SEQUENCES

55 <210> SEQ ID NO: 6
56 <211> LENGTH: 2095
!--> 57 <212> TYPE: CDNA
58 <213> ORGANISM: Homo sapiens
!--> 59 <400> SEQUENCE: 6
60 cccggctgaag catcagaatg gaagtggagga aaggcaacca gctgacacag gagccagagt 60
61 gagaccagca gactctcaca ctcaacctac accatgaatt tgtgtctatc ttctacgcgt 120
62 taagagccaa ggacaggtga agttgccaga gagca atg gct ctc ttc act ccg 173
63 Met Ala Leu Phe Thr Pro
64 1 5
66 tgg aag ttg tcc tct cag aag ctg ggc ttt ttc ctg gtg act ttt ggc 221
67 Trp Lys Leu Ser Ser Gln Lys Leu Gly Phe Phe Leu Val Thr Phe Gly
68 10 15 20
70 ttc att tgg ggt atg atg ctt ctg cac ttt acc atc cag cag cga act 269
71 Phe Ile Trp Gly Met Met Leu Leu His Phe Thr Ile Gln Gln Arg Thr
72 25 30 35
74 cag cct gaa agc agc tcc atg ctg cgc gag cag atc ctg gac ctc agc 317
75 Gln Pro Glu Ser Ser Ser Met Leu Arg Glu Gln Ile Leu Asp Leu Ser
76 40 45 50
78 aaa agg tac atc aag gca ctg gca gaa gaa aac agg aat gtg gtg gat 365
79 Lys Arg Tyr Ile Lys Ala Leu Ala Glu Glu Asn Arg Asn Val Val Asp
80 55 60 65 70
82 ggg cca tac gct gga gtc atg aca gct tat gat ctg aag aaa acc ctt 413
83 Gly Pro Tyr Ala Gly Val Met Thr Ala Tyr Asp Leu Lys Lys Thr Leu
84 75 80 85
86 gct gtg tta tta gat aac att ttg cag cgc att ggc aag ttg gag tgc 461
87 Ala Val Leu Leu Asp Asn Ile Leu Gln Arg Ile Gly Lys Leu Glu Ser
88 90 95 100
90 aag gtg gac aat ctt gtt gtc aat ggc acc gga aca aac tca acc aac 509
91 Lys Val Asp Asn Leu Val Val Asn Gly Thr Gly Thr Asn Ser Thr Asn
92 105 110 115

Does Not Comply
Corrected Diskette Needed
(pg. 1-5)

please use type (212)
DNA, PRT OR
IF IT'S DNA/RNA
please explain in section
(220)-(22)

Mandatory
please
convert
to
lowercase

RAW SEQUENCE LISTING

DATE: 07/15/2004

PATENT APPLICATION: US/10/500,841

TIME: 10:17:00

Input Set : A:\PTO.FG.txt

Output Set: N:\CRF4\07152004\J500841.raw

Same error

94	tcc act aca gct gtt ccc agc ttg gtt gca ctt gag aaa att aat gtg	557
95	Ser Thr Thr Ala Val Pro Ser Leu Val Ala Leu Glu Lys Ile Asn Val	
96	120 125 130	
98	gca gat atc att aac gga gct caa gaa aaa tgt gta ttg cct cct atg	605
99	Ala Asp Ile Ile Asn Gly Ala Gln Glu Lys Cys Val Leu Pro Pro Met	
100	135 140 145 150	
102	gac ggc tac cct cac tgt gag gga aag atc aag tgg atg aaa gac atg	653
103	Asp Gly Tyr Pro His Cys Glu Gly Lys Ile Lys Trp Met Lys Asp Met	
104	155 160 165	
106	tgg cgt tca gat ccc tgc tac gca gac tat gga gtg gat gga tcc acc	701
107	Trp Arg Ser Asp Pro Cys Tyr Ala Asp Tyr Gly Val Asp Gly Ser Thr	
108	170 175 180	
110	tgc tct ttt ttt att tac ctc agt gag gtt gaa aat tgg tgt cct cat	749
111	Cys Ser Phe Phe Ile Tyr Leu Ser Glu Val Glu Asn Trp Cys Pro His	
112	185 190 195	
114	tta cct tgg aga gca aaa aat ccc tac gaa gaa gct gat cat aat tca	797
115	Leu Pro Trp Arg Ala Lys Asn Pro Tyr Glu Glu Ala Asp His Asn Ser	
116	200 205 210	
118	ttg gcg gaa att cgt aca gat ttt aat att ctc tac agt atg atg aaa	845
119	Leu Ala Glu Ile Arg Thr Asp Phe Asn Ile Leu Tyr Ser Met Met Lys	
120	215 220 225 230	
122	aag cat gaa gaa ttc cgg tgg atg aga cta cgg atc cgg cga atg gct	893
123	Lys His Glu Glu Phe Arg Trp Met Arg Leu Arg Ile Arg Arg Met Ala	
124	235 240 245	
126	gac gca tgg atc caa gca atc aag tcc ctg gca gaa aag cag aac ctt	941
127	Asp Ala Trp Ile Gln Ala Ile Lys Ser Leu Ala Glu Lys Gln Asn Leu	
128	250 255 260	
130	gaa aag aga aag cgg aag aaa gtc ctc gtt cac ctg gga ctc ctg acc	989
131	Glu Lys Arg Lys Arg Lys Lys Val Leu Val His Leu Gly Leu Leu Thr	
132	265 270 275	
134	aag gaa tct gga ttt aag att gca gag aca gct ttc agt ggt ggc cct	1037
135	Lys Glu Ser Gly Phe Lys Ile Ala Glu Thr Ala Phe Ser Gly Gly Pro	
136	280 285 290	
138	ctt ggt gaa tta gtt caa tgg agt gat tta att aca tct ctg tac tta	1085
139	Leu Gly Glu Leu Val Gln Trp Ser Asp Leu Ile Thr Ser Leu Tyr Leu	
140	295 300 305 310	
142	ctg ggc cat gac att agg att tca gct tca ctg gct gag ctc aag gaa	1133
143	Leu Gly His Asp Ile Arg Ile Ser Ala Ser Leu Ala Glu Leu Lys Glu	
144	315 320 325	
146	atc atg aag aag gtt gta gga aac cga tct ggc tgc cca act gta gga	1181
147	Ile Met Lys Lys Val Val Gly Asn Arg Ser Gly Cys Pro Thr Val Gly	
148	330 335 340	
150	gac aga att gtt gag ctc att tac att gat att gta gga ctt gct caa	1229
151	Asp Arg Ile Val Glu Leu Ile Tyr Ile Asp Ile Val Gly Leu Ala Gln	
152	345 350 355	
154	ttc aag aaa act ctt gga cca tcc tgg gtt cat tac cag tgc atg ctc	1277
155	Phe Lys Lys Thr Leu Gly Pro Ser Trp Val His Tyr Gln Cys Met Leu	
156	360 365 370	
158	cga gtc ctt gat tca ttt ggt act gaa ccc gaa ttt aat cat gca aat	1325

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/500,841

DATE: 07/15/2004

TIME: 10:17:00

Input Set : A:\PTO.FG.txt

Output Set: N:\CRF4\07152004\J500841.raw

*Same
error*

159	Arg	Val	Leu	Asp	Ser	Phe	Gly	Thr	Glu	Pro	Glu	Phe	Asn	His	Ala	Asn	
160	375					380					385					390	
162	tat	gcc	caa	tcg	aaa	ggc	cac	aag	acc	cct	tgg	gga	aaa	tgg	aat	ctg	1373
163	Tyr	Ala	Gln	Ser	Lys	Gly	His	Lys	Thr	Pro	Trp	Gly	Lys	Trp	Asn	Leu	
164					395					400					405		
166	aac	cct	cag	cag	ttt	tat	acc	atg	ttc	cct	cat	acc	cca	gac	aac	agc	1421
167	Asn	Pro	Gln	Gln	Phe	Tyr	Thr	Met	Phe	Pro	His	Thr	Pro	Asp	Asn	Ser	
168				410					415					420			
170	ttt	ctg	ggg	ttt	gtg	gtt	gag	cag	cac	ctg	aac	tcc	agt	gat	atc	cac	1469
171	Phe	Leu	Gly	Phe	Val	Val	Glu	Gln	His	Leu	Asn	Ser	Ser	Asp	Ile	His	
172			425				430					435					
174	cac	att	aat	gaa	atc	aaa	agg	cag	aac	cag	tcc	ctt	gtg	tat	ggc	aaa	1517
175	His	Ile	Asn	Glu	Ile	Lys	Arg	Gln	Asn	Gln	Ser	Leu	Val	Tyr	Gly	Lys	
176		440				445					450						
178	gtg	gat	agc	ttc	tgg	aag	aat	aag	aag	atc	tac	ttg	gac	att	att	cac	1565
179	Val	Asp	Ser	Phe	Trp	Lys	Asn	Lys	Lys	Ile	Tyr	Leu	Asp	Ile	Ile	His	
180	455				460					465					470		
182	aca	tac	atg	gaa	gtg	cat	gca	act	ggt	tat	ggc	tcc	agc	aca	aag	aat	1613
183	Thr	Tyr	Met	Glu	Val	His	Ala	Thr	Val	Tyr	Gly	Ser	Ser	Thr	Lys	Asn	
184				475					480					485			
186	att	ccc	agt	tac	gtg	aaa	aac	cat	ggt	atc	ctc	agt	gga	cgg	gac	ctg	1661
187	Ile	Pro	Ser	Tyr	Val	Lys	Asn	His	Gly	Ile	Leu	Ser	Gly	Arg	Asp	Leu	
188			490				495						500				
190	cag	ttc	ctt	ctt	cga	gaa	acc	aag	ttg	ttt	ggt	gga	ctt	ggg	ttc	cct	1709
191	Gln	Phe	Leu	Leu	Arg	Glu	Thr	Lys	Leu	Phe	Val	Gly	Leu	Gly	Phe	Pro	
192			505				510						515				
194	tac	gag	ggc	cca	gct	ccc	ctg	gaa	gct	atc	gca	aat	gga	tgt	gct	ttt	1757
195	Tyr	Glu	Gly	Pro	Ala	Pro	Leu	Glu	Ala	Ile	Ala	Asn	Gly	Cys	Ala	Phe	
196		520				525					530						
198	ctg	aat	ccc	aag	ttc	aac	cca	ccc	aaa	agc	agc	aaa	aac	aca	gac	ttt	1805
199	Leu	Asn	Pro	Lys	Phe	Asn	Pro	Pro	Lys	Ser	Ser	Lys	Asn	Thr	Asp	Phe	
200	535				540					545				550			
202	ttc	att	ggc	aag	cca	act	ctg	aga	gag	ctg	aca	tcc	cag	cat	cct	tac	1853
203	Phe	Ile	Gly	Lys	Pro	Thr	Leu	Arg	Glu	Leu	Thr	Ser	Gln	His	Pro	Tyr	
204				555					560					565			
206	gct	gaa	gtt	ttc	atc	ggg	cgg	cca	cat	gtg	tgg	act	gtt	gac	ctc	aac	1901
207	Ala	Glu	Val	Phe	Ile	Gly	Arg	Pro	His	Val	Trp	Thr	Val	Asp	Leu	Asn	
208			570				575						580				
210	aat	cag	gag	gaa	gta	gag	gat	gca	gtg	aaa	gca	att	tta	aat	cag	aag	1949
211	Asn	Gln	Glu	Glu	Val	Glu	Asp	Ala	Val	Lys	Ala	Ile	Leu	Asn	Gln	Lys	
212			585				590						595				
214	att	gag	cca	tac	atg	cca	tat	gaa	ttt	acg	tgc	gag	ggg	atg	cta	cag	1997
215	Ile	Glu	Pro	Tyr	Met	Pro	Tyr	Glu	Phe	Thr	Cys	Glu	Gly	Met	Leu	Gln	
216		600				605					610						
218	aga	atc	aat	gct	ttc	att	gaa	aaa	cag	gac	ttc	tgc	cat	ggg	caa	gtg	2045
219	Arg	Ile	Asn	Ala	Phe	Ile	Glu	Lys	Gln	Asp	Phe	Cys	His	Gly	Gln	Val	
220	615				620					625				630			
222	atg	tgg	cca	ccc	ctc	agc	gcc	cta	cag	gtc	aag	ctt	gct	gag	ccc	ggg	2093
223	Met	Trp	Pro	Pro	Leu	Ser	Ala	Leu	Gln	Val	Lys	Leu	Ala	Glu	Pro	Gly	

RAW SEQUENCE LISTING
PATENT APPLICATION: US/10/500,841

DATE: 07/15/2004
TIME: 10:17:00

Input Set : A:\PTO.FG.txt

Output Set: N:\CRF4\07152004\J500841.raw

224 635 640 645 2095

226 cc

236 <210> SEQ ID NO: 8

237 <211> LENGTH: 24

--> 238 <212> TYPE: CDNA *please use type (212), DNA*

239 <213> ORGANISM: Artificial Sequence *PRT or if DNA/RNA, please explain in section (220) - (223).*

--> 240 <220> FEATURE:

241 <223> OTHER INFORMATION:

--> 242 <400> SEQUENCE: 8 *Mandatory.*

--> 243 gggagtgagg atgatgtagg gaag *if (213) is Artificial/unknown, please explain in section (220) - (223).*

245 <210> SEQ ID NO: 9

S 246 <211> LENGTH: 24

--> 247 <212> TYPE: CDNA *same error*

248 <213> ORGANISM: Artificial Sequence

--> 249 <220> FEATURE: *same error*

250 <223> OTHER INFORMATION:

--> 251 <400> SEQUENCE: 9

--> 252 atggggcaga ggaacttacg ttat *pls convert to lowercase*

262 <210> SEQ ID NO: 11

263 <211> LENGTH: 6

264 <212> TYPE: PRT

265 <213> ORGANISM: Homo sapiens

266 <223> OTHER INFORMATION: KRKRKK peptide *pls insert (220), whenever (221), (222) or (223) is present.*

--> 267 <400> SEQUENCE: 11

268 Lys Arg Lys Arg Lys Lys

269 1 5

271 <210> SEQ ID NO: 12

272 <211> LENGTH: 6

273 <212> TYPE: PRT

274 <213> ORGANISM: Homo sapiens

275 <223> OTHER INFORMATION: FSGGPL peptide *pls insert (220) whenever (221), (222) or (223) is present.*

--> 276 <400> SEQUENCE: 12

277 Phe Ser Gly Gly Pro Leu

278 1 5

VERIFICATION SUMMARY

DATE: 07/15/2004

PATENT APPLICATION: US/10/500,841

TIME: 10:17:01

Input Set : A:\PTO.FG.txt

Output Set: N:\CRF4\07152004\J500841.raw

:9 M:270 C: Current Application Number differs, Replaced Current Application No
 :9 M:271 C: Current Filing Date differs, Replaced Current Filing Date
 :18 M:283 W: Missing Blank Line separator, <400> field identifier
 :26 M:283 W: Missing Blank Line separator, <400> field identifier
 :34 M:283 W: Missing Blank Line separator, <400> field identifier
 :43 M:283 W: Missing Blank Line separator, <400> field identifier
 :51 M:283 W: Missing Blank Line separator, <400> field identifier
 :57 M:310 E: (3) Wrong or Missing Sequence Type, TYPE: ✓
 :59 M:283 W: Missing Blank Line separator, <400> field identifier
 :60 M:112 C: (48) String data converted to lower case, ✓
 :112 Repeated in SeqNo=6
 :232 M:283 W: Missing Blank Line separator, <400> field identifier
 :238 M:310 E: (3) Wrong or Missing Sequence Type, TYPE: ✓
 :240 M:283 W: Missing Blank Line separator, <220> field identifier
 :242 M:283 W: Missing Blank Line separator, <400> field identifier
 :242 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:8,Line#:241 ✓
 :243 M:112 C: (48) String data converted to lower case, ✓
 :247 M:310 E: (3) Wrong or Missing Sequence Type, TYPE:
 :249 M:283 W: Missing Blank Line separator, <220> field identifier
 :251 M:283 W: Missing Blank Line separator, <400> field identifier
 :251 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:9,Line#:250 ✓
 :252 M:112 C: (48) String data converted to lower case, ✓
 :258 M:283 W: Missing Blank Line separator, <400> field identifier
 :267 M:200 E: Mandatory Header Field missing, <220> Tag not found for SEQ ID#:11 ✓
 :267 M:283 W: Missing Blank Line separator, <400> field identifier
 :276 M:200 E: Mandatory Header Field missing, <220> Tag not found for SEQ ID#:12 ✓
 :276 M:283 W: Missing Blank Line separator, <400> field identifier ✓
 :284 M:283 W: Missing Blank Line separator, <400> field identifier ✓

(Sample of submitted error)



<210> 13

<211> 5

<212> PRT

<213> Homo sapiens

<400> 13

His Phe Thr Ile Gln

1

5

(10/500,841) Page 6

PCT

1/10

delete